Chengbo Han
Shenyang, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Immune Checkpoint Inhibitors in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Resistant Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer: A Meta-Analysis Based on Eight Randomized Trials.
Journal: JCO precision oncology
Published: July 10, 2025
Impact of Prophylactic Use of PEG-rhG-CSF on First-Line Immunochemotherapy in Advanced NSCLC: A Cohort Study.
Journal: JTO clinical and research reports
Published: July 10, 2024
Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-/second-generation EGFR-TKIs.
Journal: Therapeutic advances in medical oncology
Published: May 16, 2024
Sintilimab in combination with stereotactic body radiotherapy and granulocyte-macrophage colony-stimulating factor in metastatic non-small cell lung cancer: The multicenter SWORD phase 2 trial.
Journal: Nature communications
Published: March 03, 2024
Pretreatment pulmonary tumor necrosis is a promising prognostic imaging biomarker for first-line anti-PD-1/PD-L1 therapy in advanced lung squamous cell carcinoma: a multi-institutional, propensity score-matching cohort analysis.
Journal: Therapeutic advances in medical oncology
Published: December 12, 2023
Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer.
Journal: Thoracic cancer
Published: November 27, 2023
Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancer.
Journal: Thoracic cancer
Published: October 25, 2023
Impact of Drp1-Mediated Mitochondrial Dynamics on T Cell Immune Modulation.
Journal: Frontiers in immunology
Published: February 11, 2022
Sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial.
Journal: Radiation oncology (London, England)
Published: May 31, 2021
Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review.
Journal: Frontiers in oncology
Published: September 27, 2020
Combination of Radiation Therapy and Immunotherapy for Non-small Cell Lung Cancer: Peer Exchange on Frontier Academic Topics
Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer
Published: June 11, 2020
Last Updated: 09/26/2026